The US Food and Drug Administration has expanded the approval of remdesivir to high-risk COVID-19 patients who are not sick enough to be hospitalized. 

This is the same group of patients which is eligible for monoclonal antibody treatment and antiviral pills.

The treatment can be given through intravenous infusion over three consecutive days, usually at a hospital or clinic. In trial results published in December, remdesivir was reported to decrease the risk of hospitalization and death by 87% when administered to unvaccinated, high-risk COVID-19 patients in the US and Europe, within seven days of symptom onset. The study was conducted prior to the emergence of the Delta and Omicron variants; however remdesivir has been found to be potent against Omicron variant in laboratory studies… (The New York Times, January 21, 2022)